Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis |
| |
| Authors: | Shih-Pei Lin Yi-Ting Lee Shung-Haur Yang Stephanie A. Miller Shih-Hwa Chiou Mien-Chie Hung Shih-Chieh Hung |
| |
| Affiliation: | 1. Institute of Clinical Medicine, Faculty of Medicine, National Yang-Ming University, Taipei 112, Taiwan;2. Institute of Pharmacology, Faculty of Medicine, National Yang-Ming University, Taipei 112, Taiwan;3. Department of Surgery, Faculty of Medicine, National Yang-Ming University, Taipei 112, Taiwan;4. Stem Cell Laboratory, Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei 112, Taiwan;5. Orthopaedics and Traumatology, Taipei Veterans General Hospital, Taipei 112, Taiwan;6. Department of Molecular and Cellular Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA;g Graduate Institute of Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan |
| |
| Abstract: | Antiangiogenesis is an efficient therapy for eliminating colon cancers, but because of recurrence it remains only palliative. We hypothesized that certain populations of tumor cells resist antiangiogenesis-induced apoptosis and explored the underlying mechanism. We demonstrated that the CD133+ population of cells in colon cancer is resistant to anti-angiogenesis therapy. Additionally, we identified an anti-apoptotic signaling pathway responsible for this resistance involving PP2A, p38MAPK, MAPKAPK2, and Hsp27. Thus, this pathway may offer a new avenue to develop target therapy for colorectal cancer. |
| |
| Keywords: | Colon cancer Cancer stem cells Avastin Serum-free Hypoxia |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
